Antibiotics Market Poised for Strong Growth, Expected to Reach USD 65 Billion by 2030
According to Next Move Strategy Consulting, the global antibiotics market, is projected to experience significant growth, reaching USD 65 billion by 2030. This growth is expected to be fueled by a compound annual growth rate (CAGR) of 4% by 2030. Antibiotics, which are essential in treating bacterial infections and preventing their spread, continue to play a critical role in healthcare, from treating conditions like pneumonia and strep throat to aiding in the prevention of infections during surgeries.
Download Free Sample: https://www.nextmsc.com/antibiotics-market/request-sample
Market Dynamics and Key Drivers
The rising incidence of diseases such as pneumonia and sepsis, particularly in vulnerable populations like children and the elderly, is a major driver of the antibiotics market. According to the World Health Organization (WHO), pneumonia was responsible for the death of 740,180 children under five in 2019, representing 14% of all childhood deaths globally. Antibiotics like amoxicillin are crucial in combating such infections, especially in children.
Sepsis, a life-threatening condition triggered by an infection, also drives demand for antibiotics. The WHO estimates that sepsis affects 49 million people worldwide every year, causing 11 million deaths. The use of antibiotics like ceftriaxone and azithromycin for treating sepsis is expected to boost market growth as awareness and detection of this condition improve globally.
Despite the promising growth, the market faces challenges such as the high cost and potential side effects of antibiotics, including allergic reactions and gastrointestinal issues. Additionally, the emergence of antibiotic resistance poses a growing threat to global health. However, technological advancements, such as the rise of insilico medicine—which uses artificial intelligence and machine learning in drug discovery—are expected to provide new growth opportunities for the antibiotics market.
Inquire Before Buying: https://www.nextmsc.com/antibiotics-market/inquire-before-buying
Market Segmentation and Regional Insights
The antibiotics market is segmented by drug origin, route of administration, class, spectrum of activity, product, and geography. Key segments include:
- Drug Origin: Synthetic, natural, and semisynthetic antibiotics.
- Route of Administration: Intravenous, oral, and others.
- Class: Quinolones, macrolides, beta-lactams, and others.
- Spectrum of Activity: Narrow-spectrum and broad-spectrum antibiotics.
- Product Types: Penicillins, sulfonamides, fluoroquinolones, macrolides, carbapenems, cephalosporins, aminoglycosides, and others.
Geographically, North America dominates the antibiotics market, driven by high antibiotic approval rates from the U.S. Food and Drug Administration (FDA) for treating hospital-associated infections like pneumonia. A notable example includes the FDA's approval of Recarbrio, an antibiotic for hospital-acquired bacterial infections. The growing adoption of new antibiotics in hospitals and healthcare settings is expected to fuel further growth in the region.
In Asia-Pacific, the market is poised for steady growth due to the high export rates of antibiotics from countries like China, which accounted for 42.4% of global antibiotic exports by value in 2021. The region is also witnessing product approvals and collaborations aimed at improving access to antibiotics, such as a March 2022 agreement between Shionogi & Co. Ltd. and the Global Antibiotic Research and Development Partnership (GARDP).
Competitive Landscape
The antibiotics market is highly competitive, with several key players making significant strides to maintain their market share. Companies such as Wockhardt, Shionogi, Abbott Laboratories, Allergan Plc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Mylan N.V., Novartis International AG, Sun Pharmaceutical, and Teva Pharmaceutical Industries Ltd. are at the forefront of this market. These companies continue to focus on strategic product launches, regional expansions, and technological innovations.
For instance, in 2020, Wockhardt received regulatory approval for its antibiotics EMROK, which treats acute bacterial skin infections, while Shionogi launched the antibiotic cefiderocol to combat multidrug-resistant infections.
Conclusion
The global antibiotics market is set to experience significant growth driven by increasing global demand for effective treatments for pneumonia, sepsis, and other infectious diseases. However, challenges such as rising healthcare costs, antibiotic resistance, and potential side effects remain hurdles. Advances in drug discovery, particularly through artificial intelligence and machine learning, offer promising opportunities to drive the market forward. As new drugs and treatments become available, the market will continue to evolve, offering potential for both established and emerging players.
Also, Browse Related Reports:
For more information, please contact:
Next Move Strategy Consulting
E-Mail: info@nextmsc.com
Direct: +1-217-650-7991
Website: www.nextmsc.com
Follow Us: LinkedIn | Twitter | Facebook | Instagram | YouTube
About Next Move Strategy Consulting:
Next Move Strategy Consulting is a premier market research and management consulting firm that has been committed to provide strategically analysed well documented latest research reports to its clients. The research industry is flooded with many firms to choose from, what makes Next Move different from the rest is its top-quality research and the obsession of turning data into knowledge by dissecting every bit of it and providing fact-based research recommendation that is supported by information collected from over 500 million websites, paid databases, industry journals and one on one consultations with industry experts across a diverse range of industry sectors. The high-quality customized research reports with actionable insights and excellent end-to-end customer service help our clients to take critical business decisions that enables them to move beyond time and have competitive edge in the industry.
We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicates as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that range from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.